早期原发性肝癌介入化疗栓塞联合体部伽玛刀治疗与手术治疗的疗效分析

Analysis of the Clinical Effects of Transcatheter Chemoembolization Combined with Body Gamma Knife Radiotherapy vs Surgery for the Treatment of Patients with Early-stage Primary Liver Cancer

[目的]比较介入化疗栓塞联合体部伽玛刀治疗与手术治疗早期原发性肝癌的疗效.[方法]2003年至2006年在我院住院的57例早期原发性肝癌患者,其中27例采用外科根治性手术治疗（手术组）,30例采用介入化疗栓塞联合体部伽玛刀治疗（介入组）.并对两组患者的总生存时间、复发转移率及治疗副反应发生率等进行比较分析.[结果]手术组3年生存率为74.07%、介入组3年生存率为73.33%.两组患者3年生存率比较差异无统计学意义（P＞0.05）.[结论]介入化疗栓塞联合体部伽玛刀治疗早期原发性肝癌的疗效与手术治疗效果相当,对于不愿或不能手术治疗的早期原发性肝癌患者是一种较好的治疗方法.

[Objective] To compare the clinical effects of transcatheter chemoembolization combined with body gamma knife radiotherapy vs surgery for the treatment Of patients with early-stage primary liver cancer. [Methods] Fifty-seven patients with early-stage primary liver cancer were analyzed in our hospital from 2003 to 2006. Surgery group（ n =27） were treated by surgery and intervention group（ n = 30） were treated by transcatheter chemoembolization combined with body gamma knife radiotherapy. The total survival time, recurrence and metastasis rates, and side effects of the therapy between two groups were compared. [Results] The 3-year survival rate was 74.07% in surgery group and 73.33% in intervention group. There was no significant difference in 3-year survival rate between the two groups（ P 〉0.05）. [Conclusion] The clinical effect of transcatheter chemoembolization combined with body gamma knife radiotherapy is the same as that of surgery treatment for patients with early-stage primary liver cancer. It indicates that transcatheter ehemoembolization combined with body gamma knife radiotherapy is an ideal treatment method for early-stage primary liver cancer patients who don＇t agree to or cannot receive surgery.